Ms Kinga Malottki

Research Fellow

School of Cancer Sciences

Contact details

Cancer Research UK Clinical Trials Unit (CRCTU)
School of Cancer Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

About

Kinga is currently researching trials methodology for stratified medicine. She has experience of working on research methodology, systematic reviews and health technology assessments. She teaches research methods to undergraduate and postgraduate students.

Qualifications

  • Masters Degree in Economics, Warsaw School of Economics, Poland 2006
  • Masters Degree in International Relations Warsaw School of Economics, Poland 2006

Teaching

  • MBChB
  • MPH (HTA)
  • Clinical Oncology MSc

Research

  • Stratified Medicine
  • Trials Methodology
  • Systematic Reviews

Publications

Malottki K, Biswas M, Deeks J, Riley R, Craddock C, Johnson P, Billingham L. Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkers, BMJ Open 2014;4:e004188 (DOI: 10.1136/bmjopen-2013-004188)

Billingham L, Malottki K, Steven N. Small sample sizes in clinical trials: a statistician’s perspective, Clinical Investigation, July 2012, Vol. 2, No. 7, 655-57 (DOI: 10.4155/cli.12.62)

Malottki K, Barton P, Tsourapas A, Uthman A, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen Y-F. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation. Health Technology Assessment, 2011; Vol. 15: No. 14. (DOI: 10.3310/hta15140)

Connock M, Tubeuf S, Malottki K, Uthman A, Round J, Bayliss S, Meads C, Moore D. Certolizumab pegol (CIMZIA®) for the treatment of Rheumatoid Arthritis. Health Technology Assessment, 2010; Vol. 14: Suppl. 2, 1-10. (DOI: 10.3310/hta14suppl2/01)

Chen Y-F, Jowett S, Barton P, Malottki K, Hyde C, Gibbs S, et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technology Assessment 2009; Vol. 13: No.49. (DOI: 10.3310/hta13490)

Malottki K, Fry-Smith A, Moore D. Mapping the evidence base and use of neurostimulators. Report number 70, 2008, Unit of Public Health, Epidemiology and Biostatistics, University of Birmingham. ISBN: 0704427192 – 9780704427198

Back to top